DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 2)
https://doi.org/10.15789/1563-0625-2017-4-329-358
Abstract
Currently, many human infectious diseases do not developed effective methods of treatment and prevention. One of the latest successes of biotechnology is the use of adenoviral vectors carrying immunodominant antigens of various pathogens as genetically engineered vaccines both preventive and therapeutic. The use of genetic engineering technologies allows not to use in the manufacture of vaccines live viruses and bacteria, reduces the time needed for vaccine creation and production of new vaccines. Adenoviral vectors naturally penetrate into human cells, causing a rather long and significant both humoral and cellular immune response. In the second part of review, we provide information about the ongoing worldwide clinical trials of adenoviral vector-based vaccines against various infectious diseases such as influenza, malaria, Ebola haemorrhagic fever, tuberculosis, hepatitis and several others, like as to consider selection parameters of volunteers, vaccination schedule, doses of drug administration, results of completed experiments, and preliminary data on currently ongoing research.
About the Authors
L. V. Cherenova
N. Gamaleya Research Institute of Epidemiology and Microbiology
Russian Federation
Russian Federation
Cherenova Liubov V. - PhD (Biology), Research Associate, Laboratory of Molecular Biotechnology.
123098, Moscow, Gamaleya str., 18. Phone: 7 (916) 329-92-78. Fax: 7 (499) 193-61-35
T. V. Kashtigo
N. Gamaleya Research Institute of Epidemiology and Microbiology
Russian Federation
Russian Federation
PhD (Biology), Research Associate, Laboratory of Cellular Microbiology.
Moscow
Kh. S. Saiadian
First Moscow I. Sechenov State Medical University
Russian Federation
Russian Federation
PhD, MD (Medicine), Professor, Department of Pharmaceutical Technology and Pharmacology.
Moscow
M. M. Shmarov
N. Gamaleya Research Institute of Epidemiology and Microbiology
Russian Federation
Russian Federation
PhD, MD (Biology), Head, Laboratory of Molecular Biotechnology.
Moscow
References
1. Черенова Л.В., Каштиго Т.В., Саядян Х.С., Шмаров М.М. Разработка вакцин на основе аденовирусных векторов: обзор зарубежных клинических исследований (Часть1) // Медицинская иммунология, 2017. Т. 19, № 2. С. 111-126. [Cherenova L.V., Kashtigo T.V., Saiadian K.S., Shmarov M.M. Development of vaccines based on adenoviral vectors: a review of foreign clinical studies (Part 1). Meditsinskaya immunologiya = Medical Immunology (Russia), 2017, Vol. 19, no. 2, pp. 111-126. (In Russ.)] doi: 10.15789/1563-0625-2017-2-111-126.
2. Barnes E., Folgori A., Capone S., Swadling L., Aston S., Kurioka A., Meyer J., Huddart R., Smith K., Townsend R., Brown A., Antrobus R., Ammendola V., Naddeo M., O’Hara G., Willberg C., Harrison A., Grazioli F., Esposito M.L., Siani L., Traboni C.,Oo Y., Adams D., Hill A., Colloca S., Nicosia A., Cortese R., Klenerman P. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci. Transl. Med., 2012, Vol. 4, no. 115, pp. 115ra1.
3. Chuang I., Sedegah M., Cicatelli S., Spring M., Polhemus M., Tamminga C., Patterson N., Guerrero M., Bennett J.W., McGrath S., Ganeshan H., Belmonte M., Farooq F., Abot E., Banania J.G., Huang J., Newcomer R., Rein L., Litilit D., Richie N.O., Wood C., Murphy J., Sauerwein R., Hermsen C.C., McCoy A.J., Kamau E., Cummings J., Komisar J., Sutamihardja A., Shi M., Epstein J.E., Maiolatesi S., Tosh D., Limbach K., Angov E., Bergmann-Leitner E., Bruder J.T., Doolan D.L., King C.R., Carucci D., Dutta S., Soisson L., Diggs C., Hollingdale M.R., Ockenhouse C.F., Richie T.L. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One, 2013, Vol. 8, no. 2, doi: 10.1371/journal.pone.0055571
4. Churchyard G.J., Morgan C., Adams E., Hural J., Graham B.S., Moodie Z., Grove D., Gray G., Bekker L.-G., McElrath M.J., Tomaras G.D., Goepfert P., Kalams S., Baden L.R., Lally M., Dolin R., Blattner W., Kalichman A., Figueroa J.P., Pape J., Schechter M., Defawe O., De Rosa S.C., Montefiori D.C., Nabel G.J., Corey L., Keefer M.C. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One, 2011, Vol. 6, no. 8, doi: 10.1371/journal.pone.0021225.
5. De Barra E., Hodgson S.H., Ewer K.J., Bliss C.M., Hennigan K., Collins A., Berrie E., Lawrie A.M., Gilbert S.C., Nicosia A., McConkey S.G., Hill A.V. A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS. PLoS One, 2014, Vol. 9, no. 12, doi: 10.1371/journal.pone.0115161.
6. De Santis O., Audran R., Pothin E., Warpelin-Decrausaz L., Vallotton L., Wuerzner G., Cochet C., Estoppey D., Steiner-Monard V., Lonchampt S., Thierry A.C., Mayor C., Bailer R.T., Mbaya O.T., Zhou Y., Ploquin A., Sullivan N.J., Graham B.S., Roman F., De Ryck I., Ballou W.R., Kieny M.P., Moorthy V., Spertini F., Genton B. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, doubleblind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect. Dis., 2016, Vol. 16, no. 3, pp. 311-320.
7. Ewer K.J., O’Hara G.A., Duncan C.J., Collins K.A., Sheehy S.H., Reyes-Sandoval A., Goodman A.L., Edwards N.J., Elias S.C., Halstead F.D., Longley R.J., Rowland R., Poulton I.D., Draper S.J., Blagborough A.M., Berrie E., Moyle S., Williams N., Siani L., Folgori A., Colloca S., Sinden R.E., Lawrie A.M., Cortese R., Gilbert S.C., Nicosia A., Hill A.V. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat. Commun., 2013, Vol. 4, p. 2836.
8. Ewer K., Rampling T., Venkatraman N., Bowyer G., Wright D., Lambe T., Imoukhuede E.B., Payne R., Fehling S.K., Strecker T., Biedenkopf N., Krähling V., Tully C.M., Edwards N.J., Bentley E.M., Samuel D., Labbé G., Jin J., Gibani M., Minhinnick A., Wilkie M., Poulton I., Lella N., Roberts R., Hartnell F., Bliss C., Sierra-Davidson K., Powlson J., Berrie E., Tedder R., Roman F., De Ryck I., Nicosia A., Sullivan N.J., Stanley D.A., Mbaya O.T., Ledgerwood J.E., Schwartz R.M., Siani L., Colloca S., Folgori A., Di Marco S., Cortese R., Wright E., Becker S., Graham B.S., Koup R.A., Levine M.M., Volkmann A., Chaplin P., Pollard A.J., Draper S.J., Ballou W.R., Lawrie A., Gilbert S.C., Hill A.V. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. N. Engl. J. Med., 2016, Vol. 374, no. 17, pp. 1635-1646.
9. Green C.A., Scarselli E., Sande C.J., Thompson A.J., de Lara C.M., Taylor K.S., Haworth K., Del Sorbo M., Angus B., Siani L., Di Marco S., Traboni C., Folgori A., Colloca S., Capone S., Vitelli A., Cortese R., Klenerman P., Nicosia A., Pollard A.J. Chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci. Transl. Med., 2015, Vol. 7, no. 300, pp. 300ra126.
10. Green C.A., Scarselli E., Voysey M., Capone S., Vitelli A., Nicosia A., Cortese R., Thompson A.J., Sande C.S., de Lara C., Klenerman P., Pollard A.J. Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVARSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults. BMJ Open., 2015, Vol. 5, no. 10, doi: bmjopen.bmj.com/content/5/10/e008748.
11. Gurwith M., Lock M., Taylor E.M., Ishioka G., Alexander J., Mayall T., Ervin J.E., Greenberg R.N., Strout C., Treanor J.J., Webby R., Wright P.F. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect. Dis., 2013, Vol. 13, no. 3, pp. 238-250.
12. Hoft D.F., Blazevic A., Stanley J., Landry B., Sizemore D., Kpamegan E., Gearhart J., Scott A., Kik S., Pau M.G., Goudsmit J., McClain J.B., Sadoff J. A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity. Vaccine, 2012, Vol. 30, no. 12, pp. 2098-2108.
13. Ledgerwood J.E., DeZure A.D., Stanley D.A., Novik L., Enama M.E., Berkowitz N.M., Hu Z., Joshi G., Ploquin A., Sitar S., Gordon I.J., Plummer S.A., Holman L.A., Hendel C.S., Yamshchikov G., Roman F., Nicosia A., Colloca S., Cortese R., Bailer R.T., Schwartz R.M., Roederer M., Mascola J.R., Koup R.A., Sullivan N.J., Graham B.S. Chimpanzee adenovirus vector Ebola vaccine – preliminary report. N. Engl. J. Med., 2014.
14. Ledgerwood J.E., Sullivan N.J., Graham B.S. Chimpanzee adenovirus vector Ebola vaccine--preliminary report. N. Engl. J. Med., 2015, Vol. 373, no. 8, p. 776.
15. Liebowitz D., Lindbloom J.D., Brandl J.R., Garg S.J., Tucker S.N. High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial. Lancet Infect. Dis., 2015, Vol. 15, no. 9, pp. 1041-1048.
16. Milligan I.D., Gibani M.M., Sewell R., Clutterbuck E.A., Campbell D., Plested E., Nuthall E., Voysey M., Silva-Reyes L., McElrath M.J., De Rosa S.C., Frahm N., Cohen K.W., Shukarev G., Orzabal N., van Duijnhoven W., Truyers C., Bachmayer N., Splinter D., Samy N., Pau M.G., Schuitemaker H., Luhn K., Callendret B., Van Hoof J., Douoguih M., Ewer K., Angus B., Pollard A.J., Snape M.D. Safety and Immunogenicity of novel adenovirus type 26and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial. JAMA, 2016, Vol. 315, no. 15, pp. 1610-1623.
17. Ockenhouse C.F., Regules J., Tosh D., Cowden J., Kathcart A., Cummings J., Paolino K., Moon J., Komisar J., Kamau E., Oliver T., Chhoeu A., Murphy J., Lyke K., Laurens M., Birkett A., Lee C., Weltzin R., Wille-Reece U., Sedegah M., Hendriks J., Versteege I., Pau M.G., Sadoff J., Vanloubbeeck Y., Lievens M., Heerwegh D., Moris P., Guerra Mendoza Y., Jongert E., Cohen J., Voss G., Ballou W.R., Vekemans J. Ad35.CS.01-RTS,S/AS01 heterologous prime boost vaccine efficacy against sporozoite challenge in healthy Malaria-Naïve adults. PLoS One, 2015, Vol. 10, no. 7, doi: 10.1371/journal.pone.0131571.
18. O’Hara G.A., Duncan C.J., Ewer K.J., Collins K.A., Elias S.C., Halstead F.D., Goodman A.L., Edwards N.J., Reyes-Sandoval A., Bird P., Rowland R., Sheehy S.H., Poulton I.D., Hutchings C., Todryk S., Andrews L., Folgori A., Berrie E., Moyle S., Nicosia A., Colloca S., Cortese R., Siani L., Lawrie A.M., Gilbert S.C., Hill A.V. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J. Infect. Dis., 2012, Vol. 205, no. 5, pp. 772-781.
19. Ouédraogo A., Tiono A.B., Kargougou D., Yaro J.B., Ouédraogo E., Kaboré Y., Kangoye D., Bougouma E.C., Gansane A., Henri N., Diarra A., Sanon S., Soulama I., Konate A.T., Watson N.L., Brown V., Hendriks J., Pau M.G., Versteege I., Wiesken E., Sadoff J., Nebie I., Sirima S.B. A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age. PLoS One, 2013, Vol. 8, no. 11, doi: 10.1371/journal.pone.0078679.
20. Peters W., Brandl J.R., Lindbloom J.D., Martinez C.J., Scallan C.D., Trager G.R., Tingley D.W., Kabongo M.L., Tucker S.N. Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-gamma T cell responses in humans. Vaccine, 2013, Vol. 31, no. 13, pp. 1752-1758.
21. Schwartz L., Brown G.V., Genton B., Moorthy V.S. A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar. J., 2012, Vol. 11, p. 11.
22. Sedegah M., Tamminga C., McGrath S., House B., Ganeshan H., Lejano J., Abot E., Banania G.J., Sayo R., Farooq F., Belmonte M., Manohar N., Richie N.O., Wood C., Long C.A., Regis D., Williams F.T., Shi M., Chuang I., Spring M., Epstein J.E., Mendoza-Silveiras J., Limbach K., Patterson N.B., Bruder J.T., Doolan D.L., King C.R., Soisson L., Diggs C., Carucci D., Dutta S., Hollingdale M.R., Ockenhouse C.F., Richie T.L. Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS One, 2011, Vol. 6, no. 10, doi: 10.1371/journal.pone.0024586.
23. Sedegah M., Hollingdale M.R., Farooq F., Ganeshan H., Belmonte M., Kim Y., Peters B., Sette A., Huang J., McGrath S., Abot E., Limbach K., Shi M., Soisson L., Diggs C., Chuang I., Tamminga C., Epstein J.E., Villasante E., Richie T.L. Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopes. PLoS One, 2014, Vol. 9, no. 9, doi: 10.1371/journal.pone.0106241.
24. Sedegah M., Hollingdale M.R., Farooq F., Ganeshan H., Belmonte M., Huang J., Abot E., Limbach K., Chuang I., Tamminga C., Epstein J.E., Villasante E. Controlled Human Malaria Infection (CHMI) differentially affects cell-mediated and antibody responses to CSP and AMA1 induced by adenovirus vaccines with and without DNA-priming. Hum. Vaccin. Immunother., 2015, Vol. 11, no. 11, pp. 2705-2715.
25. Sheehan S., Harris S.A., Satti I., Hokey D.A., Dheenadhayalan V., Stockdale L., Manjaly Thomas Z.R., Minhinnick A., Wilkie M., Vermaak S., Meyer J., O’Shea M.K., Pau M.G., Versteege I., Douoguih M., Hendriks J., Sadoff J., Landry B., Moss P., McShane H. A Phase I, open-label trial, evaluating the safety and immunogenicity of candidate tuberculosis vaccines AERAS-402 and MVA85A, administered by prime-boost regime in BCG-vaccinated healthy adults. PLoS One, 2015, Vol. 10, no. 11, doi: 10.1371/journal.pone.0141687.
26. Sheehy S.H., Duncan C.J., Elias S.C., Biswas S., Collins K.A., O’Hara G.A., Halstead F.D., Ewer K.J., Mahungu T., Spencer A.J., Miura K., Poulton I.D., Dicks M.D., Edwards N.J., Berrie E., Moyle S., Colloca S., Cortese R., Gantlett K., Long C.A., Lawrie A.M., Gilbert S.C., Doherty T., Nicosia A., Hill A.V., Draper S.J. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One, 2012, Vol. 7, no. 2, doi: 10.1371/journal.pone.0031208.
27. Smaill F., Jeyanathan M., Smieja M., Medina M.F., Thanthrige-Don N., Zganiacz A., Yin C., Heriazon A., Damjanovic D., Puri L., Hamid J., Xie F., Foley R., Bramson J., Gauldie J., Xing Z. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci. Trans. Med., 2013, Vol. 5, no. 205, pp. 205ra134.
28. Sridhar S. Clinical development of Ebola vaccines. Ther. Adv. Vaccines, 2015, Vol. 3, no. 5-6, pp. 125-138.
29. Swadling L., Capone S., Antrobus R.D., Brown A., Richardson R., Newell E.W., Halliday J., Kelly C., Bowen D., Fergusson J., Kurioka A., Ammendola V., Del Sorbo M., Grazioli F., Esposito M.L., Siani L., Traboni C., Hill A., Colloca S., Davis M., Nicosia A., Cortese R., Folgori A., Klenerman P., Barnes E. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci. Transl. Med., 2014, Vol. 6, no. 261, pp. 261ra153.
30. Tamminga C., Sedegah M., Regis D., Chuang I., Epstein J.E., Spring M., Mendoza-Silveiras J., McGrath S., Maiolatesi S., Reyes S., Steinbeiss V., Fedders C., Smith K., House B., Ganeshan H., Lejano J., Abot E., Banania G.J., Sayo R., Farooq F., Belmonte M., Murphy J., Komisar J., Williams J., Shi M., Brambilla D., Manohar N., Richie N.O., Wood C., Limbach K., Patterson N.B., Bruder J.T., Doolan D.L., King C.R., Diggs C., Soisson L., Carucci D., Levine G., Dutta S., Hollingdale M.R., Ockenhouse C.F., Richie T.L. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS One, 2011, Vol. 6, no. 10, doi: 10.1371/journal.pone.0025868.
31. Tamminga C., Sedegah M., Maiolatesi S., Fedders C., Reyes S., Reyes A., Vasquez C., Alcorta Y., Chuang I., Spring M., Kavanaugh M., Ganeshan H., Huang J., Belmonte M., Abot E., Belmonte A., Banania J., Farooq F., Murphy J., Komisar J., Richie N.O., Bennett J., Limbach K., Patterson N.B., Bruder J.T., Shi M., Miller E., Dutta S., Diggs C., Soisson L.A., Hollingdale M.R., Epstein J.E., Richie T.L. Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection. Hum. Vaccin. Immunother., 2013, Vol. 9, no. 10, pp. 2165-2177.
32. Tapia M.D., Sow S.O., Lyke K.E., Haidara F.C., Diallo F., Doumbia M., Traore A., Coulibaly F., Kodio M., Onwuchekwa U., Sztein M.B., Wahid R., Campbell J.D., Kieny M.P., Moorthy V., Imoukhuede E.B., Rampling T., Roman F., De Ryck I., Bellamy A.R., Dally L., Mbaya O.T., Ploquin A., Zhou Y., Stanley D.A., Bailer R., Koup R.A., Roederer M., Ledgerwood J., Hill A.V., Ballou W.R., Sullivan N., Graham B., Levine M.M. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, singleblind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect. Dis., 2016, Vol. 16, no. 1, pp. 31-42.
33. Walsh D.S., Owira V., Polhemus M., Otieno L., Andagalu B., Ogutu B., Waitumbi J., Hawkridge A., Shepherd B., Pau M.G., Sadoff J., Douoguih M., McClain J.B. Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON®-TB Gold (+) Kenyan adults without evidence of tuberculosis. Vaccine, 2016, Vol. 34, no. 21, pp. 2430-2436.
34. Zhang J. Advances and future challenges in recombinant adenoviral vectored h5n1 influenza vaccines. Viruses, 2012, Vol. 4, no. 11, pp. 2711-2735.
35. Zhu F.C., Hou L.H., Li J.X., Wu S.P., Liu P., Zhang G.R., Hu Y.M., Meng F.Y., Xu J.J., Tang R., Zhang J.L., Wang W.J., Duan L., Chu K., Liang Q., Hu J.L., Luo L., Zhu T., Wang J.Z., Chen W. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet, 2015, Vol. 385, no. 9984, pp. 2272-2279.
Review
For citations:
Cherenova L.V., Kashtigo T.V., Saiadian Kh.S., Shmarov M.M. DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 2). Medical Immunology (Russia). 2017;19(4):329-358. (In Russ.) https://doi.org/10.15789/1563-0625-2017-4-329-358
Views:
2650
Email this article 